Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
IN8bio, Inc. (Nasdaq: INAB) announced a significant milestone with an oral presentation for its Phase 1 study of INB-200 at the 2023 ASCO Annual Meeting on June 2, 2023. This study evaluates the safety and efficacy of INB-200, a treatment targeting glioblastoma multiforme (GBM), a challenging brain cancer. Current treatments provide limited median progression-free survival of 6-7 months and overall survival of 14-16 months. INB-200 utilizes genetically engineered gamma-delta T cells aimed at enhancing cancer cell elimination and potentially prolonging patient survival. The abstract will be publicly accessible on ASCO's website from May 25, 2023. IN8bio also advances its DeltEx platform for developing innovative cancer therapies, currently conducting two Phase 1 trials and planning a Phase 2 trial for newly diagnosed GBM.
IN8bio, Inc. (Nasdaq: INAB) has achieved FDA orphan drug designation for its genetically modified gamma-delta T cell therapies, INB-400 and INB-410. This designation is notable as it is the first of its kind for these therapies, offering potential 7-year market exclusivity and other benefits. INB-400, an autologous therapy, has been cleared for a Phase 2 trial targeting newly diagnosed glioblastoma multiforme (GBM), with patient enrollment set to begin in the latter half of 2023. With GBM remaining a challenging cancer with limited treatment options, IN8bio's approach combines engineered gamma-delta T cells with standard treatments to enhance tumor elimination. The company anticipates further clinical developments and updates at upcoming medical meetings.
IN8bio, Inc. (Nasdaq: INAB) announced groundbreaking results from the Phase 1 trial of INB-100 for treating high-risk leukemia patients. As of April 21, 2023, all 7 evaluable patients achieved 100% complete remission (CR) and remain alive, with one patient surviving beyond 3 years. The treatment demonstrated significant gamma-delta T cell expansion, achieving an average of 82.9 times greater expansion at 60 days compared to standard care. Low-grade graft versus host disease was reported, with no dose-limiting toxicities observed. The company recommends Dose Level 2 as the next phase, expanding the trial to enroll more patients. A conference call is scheduled for April 24, 2023, to discuss these clinical updates and future directions.